Business Wire

THALES

Share
Thales Enables Teradata Vantage Customers to Protect Data at Rest With Simplicity, Speed and Scale

Thales today announced a new high-performance data security solution for Teradata customers using the Vantage platform for data and analytics. By providing users with a totally transparent and scalable encryption solution to protect data at rest in any environment, the Thales Transparent Encryption solutions enable Teradata Vantage customers to better meet compliance and privacy regulations through encryption, access controls and data access audit logging.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005043/en/

Easily deployed across files and systems, this solution enables data at rest to be quickly encrypted within the Vantage platform. Since it is “transparent”, it is simple to deploy because there are no application development or database integration changes required. The cost-effective solution removes data breach risks and supports compliance initiatives while saving organisations months on the deployment of data protection for a Teradata environment.

Effective Access Policy Management at Scale

Thales’ Transparent Encryption is completely invisible to Vantage users and administrators as long as they are authorised to access the databases and system files they won’t know that solution is protecting your business. However, processes and actions from unauthorised users are immediately stopped and logged. The solution can be flexibly deployed across physical, virtual and cloud environments, giving organisations the ability to implement granular access policies that allow administrators to access infrastructure and systems without ever being able to see sensitive data in clear text.

The solution is designed to meet the high-scale and performance requirements of Vantage deployments on-premises, in clouds and hybrid, which can be several hundred terabytes to many petabytes in size and contain highly sensitive and regulated data and subsequently subject to privacy regulations (e.g., GDPR, CCPA, etc.). The scalable solution provides little overhead, from encryption and decryption activities, letting users robustly secure data and retain critical I/O and storage efficiencies.

“We’re pleased to have worked with the Teradata team to expand the Thales offering to include the transparent encryption solutions for Teradata. Our existing joint customers will simply expand their data security platform investment to include their Vantage environment. They will find that the policies for encryption, privileged user access and the additional security intelligence logs to further enhance their visibility are entirely familiar. New customers will be taking their first steps in unifying all their data security requirements and use cases on one easy to use, scalable and high-performance platform. The Thales solution complements the rich set of controls in the Vantage environment, ensuring that deployments meet the toughest regulatory audit scrutiny and protects a company’s most valuable data,” said Todd Moore, Senior Vice President, Encryption Solutions at Thales .

Jay Irwin JD, Director of Teradata Center for Enterprise Security added: "Teradata’s customer base is comprised of some of the largest and most data-centric companies on the planet. Security at scale is vital to this clientele, which makes Thales’ solution a particularly good fit for enabling Teradata's best-in-industry cloud security to be even more robust. With the application of Thales transparent encryption solutions, we provide a layered defense that protects customer data on-premises, in the cloud and in hybrid environments – all deployment types that our customers use today.”

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group
Market page

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release

RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c

Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release

Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p

Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release

Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye